Key Highlights

  • Revenue increased 12.2% to USD 80.7 million in the third quarter, with equipment and Supply sales up 23.7% and ventilator rentals up 7.4%.
  • Net income attributable to the company climbed 32.0% to USD 4.6 million, or USD 0.11 per diluted share, from USD 0.09 a year earlier.
  • Adjusted EBITDA, a non-GAAP measure, reached USD 17.1 million versus USD 16.1 million, while gross Margin came in at 57.3% against 57.5%.
  • PAP therapy patients rose to 43,861 from 31,891 a year earlier, and ventilator patients totaled 12,552.

Sleep Therapy and Women's Health Drive Growth

Viemed Healthcare (NASDAQ:VMD) submitted its third-quarter filing on November 4, 2026, for the period ending September 30, 2026. As a home medical equipment company focused on post-acute breathing care, ventilator rentals still generate the largest share of revenue, although that share eased to 46.4% from 48.5%. Management pointed to sleep therapy, complex respiratory services and women's health items as the drivers behind a 12.2% Revenue increase. Equipment rentals other than ventilators grew 13.1% to USD 17.4 million, and service income climbed 7.7% to USD 6.4 million. Nine-month Net Income attributable to shareholders reached USD 10.0 million, up from USD 9.3 million, while diluted EPS was USD 0.24 against USD 0.23. The Business serves patients in every U.S. state. Third-quarter revenue had been USD 71.9 million a year before.

Margin Mix Shifts as Supply Sales Outgrow Rentals

Gross profit advanced 11.7% to USD 46.2 million, but the margin slipped as equipment and supplies, which Yield less than rentals, grew to 32.0% of sales from 30.1%. Selling, general and administrative costs absorbed 44.0% of revenue, compared with 44.4% previously. Operating Income increased 23.4% to USD 7.0 million, and interest costs fell to USD 0.2 million from USD 0.5 million. Sleep resupply patients numbered 40,918, compared with 33,518 a year prior. Cash stood at USD 9.7 million on September 30, 2026. Adjusted EBITDA of USD 17.1 million was about 24.4% higher than the USD 13.7 million posted in the second quarter (calculated). The workforce included 432 licensed respiratory therapists, roughly 29% of employees.

Ventilator Policy and Reimbursement Risks

Ventilator patients totaled 12,552, barely above the 12,372 of a year earlier and below the 12,635 in the previous quarter. A Medicare national coverage determination finalized in June 2025 defined medical necessity standards for home ventilators, and the company argues this could materially shape its operations. Starting January 1, 2028, the next competitive bidding cycle will leave out ventilators, PAP devices and oxygen. Medicare represents 25% of net receivables. Pricing pressure from payers and Tariff costs passed through suppliers are additional threats, and consolidation among payers strengthens their bargaining power. Viemed says inflation-linked reimbursement agreements, buying power and technology help absorb cost increases. R&D expense is expected to stay steady through the remainder of 2026.

Where Things Stand

Operating leverage did the heavy lifting, as operating income rose 23.4% while selling costs grew more slowly than sales and interest costs fell. Viemed Healthcare (NASDAQ:VMD) converted 12.2% revenue growth into 23.4% higher operating income and 32.0% higher net income. Growth now leans more on sleep therapy and supplies than on ventilators, shifting the mix. Next markers are ventilator patient trends, the effect of Medicare coverage criteria and whether supplies keep outpacing rentals. The filing carried no numeric guidance, and revenue rose from USD 71.9 million a year earlier to USD 80.7 million.